NCCN guidelines® insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines
…, R Grisham, A Hakam, A Jain, A Karam… - Journal of the National …, 2022 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years following diagnosis. The NCCN …
United States, with less than half of patients living> 5 years following diagnosis. The NCCN …
Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology
…, R Grisham, A Hakam, A Jain, A Karam… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United
States and is the country’s fifth most common cause of cancer mortality in women. A major …
States and is the country’s fifth most common cause of cancer mortality in women. A major …
Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease
A Karam, O Dorigo - Gynecologic oncology, 2012 - Elsevier
OBJECTIVE: The outcome of patients with invasive Extramammary Paget's disease (EMPD)
is poorly studied. The goal of the current study was to analyze the incidence, treatment …
is poorly studied. The goal of the current study was to analyze the incidence, treatment …
Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer
JD Carpini, AK Karam, L Montgomery - Angiogenesis, 2010 - Springer
Tumor neovascularization is a complex process that plays a crucial role in the development
of many different types of cancer. Vascular endothelial growth factor (VEGF) is a potent …
of many different types of cancer. Vascular endothelial growth factor (VEGF) is a potent …
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
…, GE Konecny, M Fekete, KYM Chen, A Karam… - Clinical Cancer …, 2011 - AACR
Purpose: This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-BEZ235
in preclinical models of ovarian cancer as a potential novel therapeutic strategy. …
in preclinical models of ovarian cancer as a potential novel therapeutic strategy. …
When to operate, hesitate and reintegrate: society of gynecologic oncology surgical considerations during the COVID-19 pandemic
…, AK Sinno, M Leitao, MA Martino, A Karam… - Gynecologic …, 2020 - Elsevier
The COVID-19 pandemic has challenged our ability to provide timely surgical care for our
patients. In response, the US Surgeon General, the American College of Srugeons, and other …
patients. In response, the US Surgeon General, the American College of Srugeons, and other …
Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy
A Karam, N Feldman, CH Holschneider - Nature Clinical Practice …, 2007 - nature.com
Background A 28-year-old Hispanic gravida 1 was found to have a 4–5 cm cervical mass
when she presented at 23 weeks gestation. On pelvic examination, the tumor was shown to …
when she presented at 23 weeks gestation. On pelvic examination, the tumor was shown to …
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer
A Santillan, AK Karam, AJ Li, R Giuntoli II… - Gynecologic …, 2007 - Elsevier
OBJECTIVES: To evaluate the feasibility and associated survival outcome of secondary
cytoreductive surgery in patients with isolated lymph node recurrence of epithelial ovarian cancer…
cytoreductive surgery in patients with isolated lymph node recurrence of epithelial ovarian cancer…
Ovarian cancer: the duplicity of CA125 measurement
AK Karam, BY Karlan - Nature reviews Clinical oncology, 2010 - nature.com
Since it was first described in 1981, CA125 has held an important role in monitoring patients
with ovarian cancer. CA125 is elevated in 80% of patients with epithelial ovarian cancer at …
with ovarian cancer. CA125 is elevated in 80% of patients with epithelial ovarian cancer at …
HER-2/neu targeting for recurrent vulvar Paget's disease: a case report and literature review
A Karam, JS Berek, A Stenson, JY Rao, O Dorigo - Gynecologic oncology, 2008 - Elsevier
BACKGROUND: The treatment of Paget's disease of the vulva particularly for recurrences can
be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of …
be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of …